The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).
 
Dustin A. Deming
Consulting or Advisory Role - Acrotech Biopharma; Array BioPharma; Bayer; Bristol-Myers Squibb; Genentech/Roche; Novocure; Promega; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Revolution Medicines (Inst)
 
Philip Emmerich
No Relationships to Disclose
 
Anita Ahmed Turk
No Relationships to Disclose
 
Sam Joseph Lubner
Employment - Mitra Biotech
Leadership - Mitra Biotech
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - AstraZeneca; EMD Serono; Flatiron Health; Gerson Lehrman Group; Incyte; ipsen; LEK; Lilly; Lilly; M3; Taiho Pharmaceutical
Research Funding - EMD Serono (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Noelle K. LoConte
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Celgene
 
Daniel Mulkerin
No Relationships to Disclose
 
David H. Kim
Stock and Other Ownership Interests - Cellectar; Elucent Medical
 
Kristina A. Matkowskyj
No Relationships to Disclose
 
Sharon M. Weber
No Relationships to Disclose
 
Daniel Abbott
Consulting or Advisory Role - PatientPoint
 
Jens C. Eickhoff
Consulting or Advisory Role - Five Prime Therapeutics
Research Funding - Sanofi Pasteur (Inst)
 
Michael Frederick Bassetti
Research Funding - AstraZeneca; EMD Serono; Merck